With a worldwide prevalence of 0.9% across age groups (≤4.6% in individuals older than 65 years),^[@R1]^ essential tremor (ET) is one of the most common human movement disorders. ET is characterized by involuntary oscillations of a body part, primarily in upper limbs, during postural control and voluntary motion.^[@R2],[@R3]^ Despite strong evidence supporting ET to be an inherited predisposition, very few predisposing genes have been identified.^[@R4]^ Recently, a 2-stage genome-wide association study (GWAS) using 2,807 cases and 6,441 controls of European descent^[@R5]^ was reported. This study revealed disease associations for intronic variants within 3 genes: a serine/threonine kinase (*STK32BI*), a transcriptional coactivator (*PPARGC1A*), and a cell-adhesion molecule (*CTNNA3*). The authors performed linkage disequilibrium analysis and showed no additional associated markers in neighboring genes. This study aims to establish whether coding variants from these genes might be associated with ET. Because low-frequency and rare variants are not tagged by conventional genome-wide genotyping arrays, they may represent an important and understudied component of complex trait genetics. Using higher resolution methods to interrogate variants across the entire frequency spectrum, this study has the potential to find additional evidence to support the role of the genes in the disease etiology.

METHODS {#s1}
=======

Patients were recruited in different centers across Canada, and a senior neurologist trained to evaluate movement disorders reviewed their ET diagnoses. Exclusion criteria included (1) an identified cause of exaggerated physiologic tremor, (2) presence of other neurologic deficits (parkinsonisms, polyneuritis, and others), and (3) an orthostatic tremor or (4) a psychogenic-like tremor. Signed written informed consent forms were obtained from each individual studied.

In an effort to identify potentially deleterious variants in the genes recently associated with ET by GWAS, we first examined the whole-exome and whole-genome sequencing (WES/WGS) data from 54 cases across 14 multiplex families with autosomal dominant ET. Secondly, we selected 269 unrelated patients with ET and 287 ethnically matched unrelated individuals with no neurologic disorder is known for a case-control study. European decent participants were recruited from Canadian movement disorder clinics. Targeted massive parallel sequencing was performed across the coding regions of *STK32B* (NM_018401), *PPARGC1A* (NM_013261), and *CTNNA3* (NM_013266). Read mapping, variant calling, and quality controls (QCs) are described in the supplementary material at [Neurology.org/ng](http://ng.neurology.org/lookup/doi/10.1212/NXG.0000000000000195). A total of 34 variants passed the QC validation.

Single-variant case-control associations were analyzed using a Fisher exact test (PLINK v1.90).^[@R6]^ In addition, a gene-based, variance-component test was performed using an optimal sequence kernel association test (SKAT-O).^[@R7],[@R8]^ Results were considered statistically significant when *p* values were ≤0.05 after Bonferroni correction for multiple testing.

RESULTS {#s2}
=======

All familial ET samples for which WES or WGS data were available had ≥97% of the targeted sequences covered at ≥15X. After genotype and variant QC, 12 variants were identified and 7 of these altered the amino acid sequence. Only 1 variant (*CTNNA3* c.1453A\>T) was rare in the general population (frequency \<0.01 in Exome Aggregation Consortium \[ExAC\]) databases,^[@R8]^ but it was observed only in 3 of the 4 affected individuals of a single family. Despite the absence of segregating rare deleterious variants across familial cases, we proceeded with the analysis of the targeted sequencing in cases and controls. After removing poorly captured samples (n = 8), the remaining ones had ≥80% of the targeted sequences covered at \>15X, and 34 coding variants were identified. Briefly, 20 nonsynonymous variants were found, among which 3 were common ones (frequency \>0.01 in ExAC) and 17 were rare. In addition, we found 1 rare nonframeshifting deletion in *STK32B* of a control individual; unfortunately, no DNA from family members was available to test for co-segregation with the phenotype (see table e-1 for a detailed list of variants).

Of the 34 single nucleotide polymorphisms identified, none had a significantly different allelic distribution between cases and controls (Fisher exact test after Bonferroni correction). To assess the cumulative impact of rare variants, we performed SKAT-O analyses using (1) all variants, (2) only rare variants, and (3) only the rare variants altering the mRNA. Using individual genes as bin delimiters, none of the SKAT-O tests led to a rejection of the null hypothesis (*p* \> 0.05 after Bonferroni correction); thus, no difference in variant distribution for any of the genes was observed between the ET cases and the controls.

DISCUSSION {#s3}
==========

In this study, we performed a combination of exonic and targeted DNA sequencing of 3 genes. ET-affected cases and matching controls from European descents were recruited to identify rare variants associated with ET. Genes were chosen for analysis on the basis of a recently published study that showed association between variants located in their intronic regions and ET. It is important that this previous study relied on GWAS approaches, which generally do not interrogate rare genetic variants.

Both an examination of WES/WGS data obtained from a cohort of familial ET cases and a case-control study (Canadians of European decent) analysis failed to identify additional *STK32B*, *PPARGC1A*, and *CTNNA3* variants that are associated with ET. Although a few rare coding variants were identified across the genes, SKAT-O did not reveal those to have a cumulative effect toward ET. Rare variants are inherently uncommon, and the size of the cohorts examined here was modest. Making an allowance for the genetic heterogeneity of ET and that up to 50% of individuals diagnosed with ET have been suggested to be misdiagnosed,^[@R9]^ it is likely that the increased power of detection of a larger cohort might be warranted to further validate these genes. Nonetheless, this study identified coding variants in 3 genes recently associated with ET.^[@R5]^

Supplemental data at [Neurology.org/ng](http://ng.neurology.org/lookup/doi/10.1212/NXG.0000000000000195)
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